SAN FRANCISCO, Nov. 3 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that it will announce early positive data from the ongoing Phase 1-2 trial of the company's selective androgen receptor modulator, MDV3100, in hormone refractory prostate cancer before the markets open on Monday, November 5, 2007. A conference call and live webcast will be held at 8:30 a.m. Eastern Time on Monday to discuss these data.
Conference Call Details
To access the live conference call Monday, November 5, 2007 at 8:30 a.m. Eastern Time via phone, please dial 800-930-7616 from the United States and Canada or +1913-312-0684 internationally. The conference ID is 5441900. Please dial in approximately ten minutes prior to the start of the call. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com/ and clicking on the "Investor Relations" section. A replay of the webcast will be available on the Company's website for 30 days.
About Medivation
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com/.
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006, include more information about factors that could affect the Company's financial and operating results.
